An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model

Journal of Medical Virology
Shaohui SongGuoyang Liao

Abstract

At the same dosage, the new generation of Sabin-inactivated poliovirus vaccine (sIPV) is less immunogenic than the traditional oral polio vaccine (OPV) dosage in China. The useful adjuvant might be a necessary strategy to strengthen the immune protective effects. In this study, we produced an adjuvant compound (named KML05) that could promote immunogenicity and fractional doses of sIPV with a long duration of protection in a rat model. The compound adjuvant had both advantages and a function of MF59 and carbopol971P. The effect seroconversion of experimental animals immunized with KML05 could be extended to one-eighth of the dose. According to the result of the geometric mean titers (GMTs), KML05 adjuvant could save eight times the amount of sIPV D-antigen usage, but aluminum hydroxide adjuvant could save twice at the same titers. Additionally, it was found that there was a significant difference in the GMT titer of poliovirus type 2 between animals immunized by KML05 and alum adjuvant (P < 0.05). At 12th-month postvaccination, the neutralization titers stimulated by IPV-KML05 were maintained over a longer time period in immunized animals. Our research team developed KML05 adjuvant, which combined carbopol971P with MF59, increa...Continue Reading

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Bonadonna
May 1, 1984·Reviews of Infectious Diseases·R H Bernier
Apr 1, 1994·Epidemiology and Infection·J A MumfordD M Jessett
Jul 29, 2000·Drug Development and Industrial Pharmacy·A K SinglaA Singh
Sep 13, 2005·Annual Review of Microbiology·Olen M KewMark A Pallansch
Oct 28, 2010·American Journal of Epidemiology·Neal Nathanson, Olen M Kew
Apr 22, 2011·Expert Review of Vaccines·Derek T O'HaganGiuseppe Del Giudice
Dec 22, 2012·Expert Review of Vaccines·Derek T O'HaganGiuseppe Del Giudice
Dec 18, 2013·Vaccine·Benjamin P SteilMario Barro
Nov 30, 2016·Vaccine· World Health Organization
Jan 13, 2018·Lancet·Michel ZaffranJay Wenger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.